Resmed shares are at an 'attractive valuation' and could be a 'great buying opportunity': fund manager

This beaten-up stock could be a healthy opportunity.

| More on:
ventilator mask

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Resmed (ASX: RMD) share price has suffered a significant sell-off over the last few months, as we can see on the chart below. Since 2 August 2023, the ASX healthcare share has declined 34%. Over that same time period, the S&P/ASX 200 Index (ASX: XJO) has fallen just 3.5%.

After such a major fall of a blue chip healthcare stock, it's unsurprising that a number of fund managers have been reviewing the business to see if they think it's an opportunity.

What's the problem?

Ophir Asset Management has explained that there were three triggers that may have caused the decline in the Resmed share price.

First, the gross profit margin "disappointed" in its latest earnings result, compared to the expectation that there would be an improvement as supply chain issues subsided.

Second, investor concerns grew around competition from a new wave of GLP-1 weight loss drugs.

Third, there's the looming re-entry of competitor Phillips into the market after its June 2021 product recall.

Ophir noted that the supply chain issue is "temporary" and there was news in early October that the FDA will push back the timeline for Phillips to re-enter the market. But, the weight loss drugs such as Ozempic and Wegovy are creating the most uncertainty.

The drugs could be a major headwind because being overweight is reportedly a "key risk factor" for obstructive sleep apnea (OSA), with 58% to 70% of sleep apnea cases being "directly related to excess weight gain".

Ophir acknowledged that the weight loss drugs "will likely impact the total addressable market for Resmed" and that will impact the 'funnel' of new patients for Resmed devices.  

However, the scale of the impact is "highly uncertain". That includes "supply constraints, lagging real-world efficacy, side effects, low drug compliance, high cost and lack of insurer coverage."

The fund manager noted the potential for people to put on more weight than they lost after stopping using the drug.

Why could the Resmed share price be an opportunity?

Ophir explained:

Treatment for OSA is still a large and underpenetrated market. Resmed's revenue would have grown historically at the same rate even if its TAM was halved. This is because the limiting factor on Resmed growth to date has been the capacity to diagnose those with OSA and prescribe CPAP devices.

Further there is also still a significant population that suffer from OSA for non-weight related reasons (i.e. age and physical traits).

The fund manager said that it will continue to maintain a core position in the business and suggested that at the current valuation, it could be a "great buying opportunity" at five-year lows (and also cheaper than competitors).

However, Ophir also mentioned that it may not be a great buy in a scenario where it's currently "overearning currently compared to what it may earn in the future, depending on the Philips recall and future impact of the new wave of weight loss drugs."

The fund manager owns Resmed shares as a core position in the portfolio, saying that the "attractive valuation it currently trades on outstrips the risks it faces". But it's keeping a very close eye on the company before buying any more.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »